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Background and Objectives 
 
Prion diseases, or transmissible spongiform encephalopathies (TSEs), are infectious fatal 
neurodegenerative disorders that include a variety of human diseases, such as Creutzfeldt-
Jacob disease (CJD), Gerstmann-Sträussler-Scheinker syndrome (GSS), kuru and fatal familial 
insomnia [1, 2]. Mammalian prion protein (PrP) in an abnormal aggregation-prone self-
perpetuating (prion) conformation has been implicated as a TSE infectious agent. However, the 
mechanism of conversion of this protein into a prion conformation is poorly understood, thus 
preventing efficient development of both therapeutic interventions and prophylactic measures, 
targeting prion diseases. Although mutations leading to the heritable form of human prion 
diseases have been uncovered, primary effects triggering prion formation by mutant proteins 
were difficult to investigate due to the complexity of both experimental models and physiological 
effects of the disease. Proteins capable of producing the self-perpetuating (prion) conformations 
have also been identified in yeast [3, 4]. The power of yeast genetics and molecular biology has 
led to tremendous progress in understanding yeast prions. However, yeast prion proteins are 
not homologous to mammalian PrP. This prevented direct extrapolation of yeast data to 
mammalian and human prion diseases.   
 
Our project utilized relatively cheap and powerful techniques of yeast genetics for studying prion 
properties of mammalian PrP. This enables us to uncouple the molecular events leading to a 
disease from their physiological consequences. Our approach allows molecular dissection of the 
prionogenic properties of mammalian PrP via genetic analysis in yeast, and paves the way for 
developing the new therapeutic or prophylactic treatments aimed at prion and amyloid 
disorders.  
  
The overall goal of the project was to establish a yeast-based model for studying the molecular 
mechanism of prion formation by mammalian PrP protein. Our experimental assay is based on 
detection of the changes in the conformation and/or aggregation state of a mammalian protein 
via the subsequent heritable conformational change in a yeast protein, fused to it. Prion 
formation by yeast protein leads to an easily detectable phenotype, that is, growth on a certain 
selective medium. We introduced alterations, known to cause or prevent prion diseases in 
mammals or humans, into a PrP portion of the chimeric protein, and studied effects of these 
mutations on prion induction by chimeric protein in yeast. This tells us how and at which stages 
these mutations influence prion formation. New alterations affecting prion formation can also be 




PrP prion produces cross-β fibrous aggregates (amyloids) in the infected brains. The likely 
mechanism of prion formation is immobilization of the monomeric protein into amyloidogenic 
polymers, accompanied by conversion into the β-rich conformation [1, 2]. For heritable TSEs 
(including heritable forms of CJD), either prion formation or its propagation are promoted by a 
mutation in PrP [2, 5]. However, systematic studies of the mechanisms by which mutations 
influence a prion were difficult due to high complexity of the experimental models and disease-
associated phenotypes. Sporadic prion diseases probably originate from spontaneous 
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nucleation of PrP polymers. However, due to low frequency and long incubation periods, this is 
essentially impossible to study in mammals. 
 
Proteins that form self-perpetuating cross-β polymers, similar to mammalian prions, have also 
been identified in yeast. One example is Sup35, a translation termination factor [3,4]. Its N-
terminal region (Sup35N) is responsible for prion properties, while the C-terminal region 
functions in translation. Conversion of Sup35 into a prion results in the readthrough of stop 
codons, a phenotype that is easily detectable by growth in the specially designed yeast strains 
[3].  
 
Our approach (Fig. 1) employs the chimeric construct (called N-PrP), in which yeast Sup35N is 













[2, 5]. We 
have shown 
that 
introduction of N-PrP into a yeast cell greatly increases efficiency of the initial nucleation of 
Sup35 prion in the absence of any pre-existing prions. Newly nucleated prion incorporates full-
size Sup35, allowing detection by growth assay (Fig. 1B). Thus, PrP-promoted nucleation is 
fixed in the form of a readily detectable yeast prion.  In such a design, amyloidogenic properties 
of a mammalian protein can be monitored via prion formation by the yeast protein, that is easily 
detectable at phenotypic level. Biochemical (centrifugation and detergent insolubility) and 
cytological (secondary immunofluorescence) approaches were used to confirm N-PrP 




Our preliminary data, showing that N-PrP promotes de novo prion formation in yeast in the 
absence of any pre-existing prions, have been reproduced by using constructs under two 
different inducible promoters, namely the copper-inducible promoter (as shown on Fig. 2A) and 
galactose-inducible promoter (not shown). This result confirms that observed effects are not 
related to chemicals that were used to induce N-PrP expression in yeast. 
 
Our preliminary data showing that deletion of the PrP residues 90-120, knocking out prion 
propagation in mammals [2, 5], also antagonizes prion nucleation in yeast, have been confirmed 
(Fig. 2A). We have also demonstrated that deletion 90-120 does not influence the levels of the 





























Figure 1. Scheme of prion nucleation in yeast. A – Excess Sup35N induces [PSI+] prion efficiently
only in the presence of another prion ([PIN+]). B – Chimeric Sup35N-PrP induces [PSI+] in the absence
of [PIN+]. [PSI+] is detected as on Fig. 1A. Circles and squares correspond to non-prion and aggregated
(prion) isoforms, respectively. Ellipse corresponds to the non-prion region of Sup35.
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We have shown that 
N-PrP constructs 
with the deletions of 
the C-terminal region 
(after amino acid 
positions 160 or 172) 
promote de novo 
prion formation in 
yeast with the 
significantly higher 
frequency, compared to the original N-PrP construct (Fig. 2A). Nonsense-mutation at position 
160 of human PrP, generating a protein that is similar to one of our C-terminal deletions (Δ160), 
is associated with the heritable form of prion disease in human [6]. The other deletion (Δ172) 
represents a new alteration whose effect was not known previously. Increased promotion of 
prion formation occurs despite the fact that the same deletions decrease rather than increase 
levels of N-PrP protein produced in yeast. The most plausible explanation is that C-terminal 
deletions destabilize the N-PrP construct, leading to both increased degradation and increased 
aggregation (followed by prion formation). This agrees with some models of mammalian PrP 
structure.   
 
We have shown that while most of the N-PrP protein accumulated in the absence of pre-existing 
prions is soluble in detergents, N-PrP overproduction leads to formation of the small but 
detectable detergent-resistant polymeric fraction (Fig. 2B) as expected of an amyloid. N-PrP 
overproduction also promotes formation of filamentous cytologically detectable aggregates, 
associated with de novo prion formation [7,8], by GFP-tagged Sup35. This suggests that 
promotion of de novo prion formation by N-PrP occurs through generation of the transient 
aggregate structures. 
 
Prions exist in multiple variants or “strains” [1-4]. Even if most of the N-PrP prions, initially 
formed in yeast, are transient and unstable, some rare variants capable of stable propagation 
might appear. To identify them, we have transiently overexpress chaperone Hsp104 in the 
[PSI+] isolates, induced in the presence of overproduced N-PrP. Excess Hsp104 cures [PSI+] 
but not other prions [3,9,10]. Resulting [psi-] colonies (retaining N-PrP) were screened for de 
novo [PSI+] nucleation at normal levels of N-PrP (without overproduction). Dependence of the 
“nucleation” phenotype of N-PrP and absence of the other known prions was confirmed by 
genetic and biochemical assays.  One N-PrP isolate capable of inducing Sup35 prion without 
overproduction was identified. It is curable by guanidine hydrochloride, as expected of a yeast 
prion. As per our model, this isolate should contain a prion form of N-PrP controlled through its 




1. New assay for studying the prion properties of mammalian prion protein in yeast is 
developed. This assay is based on the ability of a chimeric protein, composed of the 
fragments from yeast prion protin Sup35 and mammalian PrP, to nucleate de novo 
formation of the yeast prion in the absence of any known pre-existing prions.  
2. The region of mammalian PrP protein encompassing the amino acid positions 90 through 
120, that is required for prion propagation in mammals, is also essential for  prion formation 








Figure 2. Effects of PrP on prion
nucleation in yeast. A – PrP deletion Δ90-
120, eliminating susceptibility to prion
disease in mammals, abolishes prion
nucleation in yeast, while C-terminal
deletions Δ160-230 and Δ172-230 increase
prion nucleation. B – Small fraction of
polymerized N-PrP is detected on the top of
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3. Deletion of the C-terminus of PrP protein after amino acid position 160, resembling a form 
generated in one of the heritable prion diseases in humans, also increases de novo prion 
formation in yeast. 
4. New PrP alteration promoting de novo prion formation (deletion of the C-terminus after 
position 172) is detected by using yeast assay. 
5. Prion induction in yeast is accompanied by the formation of the detergent-insoluble fraction 
of a chimeric protein. 
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